Alnylam Pharmaceuticals (ALNY) revenue
Alnylam Pharmaceuticals (ALNY) reported revenue of $3.71B in fiscal 2025 (the year ended December 31, 2025). That is 65.2% higher than the $2.25B of fiscal 2024. Figures as of 19 Nov 2026, 11:18 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Revenue, fiscal 2025
- $3.71B
- Change on fiscal 2024
- +65.2%
- Growth, 5 years
- +49.8% a year
- Highest on record
- $3.71Bfiscal 2025
- Lowest on record
- $47.16Mfiscal 2016
- Fiscal years on record
- 132008–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Alnylam Pharmaceuticals revenue, in more detail
Over the five fiscal years to 2025 revenue grew at a compound 49.8% a year. Across the 13 fiscal years on record (2008–2025), the highest was $3.71B in fiscal 2025 and the lowest $47.16M in fiscal 2016.
Revenue by fiscal year
Alnylam Pharmaceuticals revenue, year by year
| Fiscal year | Revenue | Change | Year ended |
|---|---|---|---|
| 2025 | $3.71B | 65.2% up | |
| 2024 | $2.25B | 23.0% up | |
| 2023 | $1.83B | 76.2% up | |
| 2022 | $1.04B | 22.9% up | |
| 2021 | $844.29M | 71.3% up | |
| 2020 | $492.85M | 124.3% up | |
| 2019 | $219.75M | 193.4% up | |
| 2018 | $74.91M | 16.7% down | |
| 2017 | $89.91M | 90.7% up | |
| 2016 | $47.16M | — | |
| 2010 | $100.04M | 0.5% down | |
| 2009 | $100.53M | 4.5% up | |
| 2008 | $96.16M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.
How to read it
Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.
Revenue at health care companies of similar size
| Company | Revenue | Fiscal year |
|---|---|---|
| BioNTech BNTX | €2.87B | 2025 |
| Alnylam Pharmaceuticals ALNY | $3.71B | 2025 |
| Medpace Holdings MEDP | $2.53B | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Alnylam Pharmaceuticals, figure by figure
- Alnylam Pharmaceuticals market cap
- Alnylam Pharmaceuticals earnings
- Alnylam Pharmaceuticals earnings per share (EPS)
- Alnylam Pharmaceuticals P/E ratio
- Alnylam Pharmaceuticals P/S ratio
- Alnylam Pharmaceuticals P/B ratio
- Alnylam Pharmaceuticals free cash flow
- Alnylam Pharmaceuticals operating margin
- Alnylam Pharmaceuticals dividend
- Alnylam Pharmaceuticals shares outstanding
- Alnylam Pharmaceuticals total debt
- Alnylam Pharmaceuticals cash on hand
- Alnylam Pharmaceuticals total assets
- Alnylam Pharmaceuticals total liabilities
- Alnylam Pharmaceuticals net assets (shareholders' equity)
- Alnylam Pharmaceuticals return on equity (ROE)
- Alnylam Pharmaceuticals return on invested capital (ROIC)
Alnylam Pharmaceuticals (ALNY) overview: price, valuation and scorecardAll health care companies by market value
Alnylam Pharmaceuticals revenue: questions and answers
What is Alnylam Pharmaceuticals's revenue?
Alnylam Pharmaceuticals (ALNY) reported revenue of $3.71B in fiscal 2025 (the year ended December 31, 2025). That is 65.2% higher than the $2.25B of fiscal 2024.
What is the growth rate of Alnylam Pharmaceuticals's revenue?
Over the five fiscal years to 2025 revenue grew at a compound 49.8% a year.
What are the highest and lowest revenue figures on record for Alnylam Pharmaceuticals?
Across the 13 fiscal years on record (2008–2025), the highest was $3.71B in fiscal 2025 and the lowest $47.16M in fiscal 2016.
How is Alnylam Pharmaceuticals's revenue calculated?
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Alnylam Pharmaceuticals it is on record here for 13 fiscal years, 2008 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: revenue
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Alnylam Pharmaceuticals (ALNY) revenue”, data as of 19 November 2026. https://funkfolio.com/stock/ALNY/revenue
Underlying data: the company's filings with the SEC and Yahoo Finance.